Summary
Definition
History and exam
Key diagnostic factors
- história familiar de CMH
- história de pré-síncope ou de síncope
- sopro sistólico de ejeção
- elevação ventricular esquerda (ictus)
- impulso apical duplo ou dupla pulsação da carótida
- história familiar de morte súbita
Other diagnostic factors
- homem mais jovem (<50 anos de idade)
- dispneia
- angina
- palpitações
- pulso irregularmente irregular
- mulher de idade mais avançada (>50 anos de idade)
- colapso
- quarta bulha cardíaca
Risk factors
- história familiar de cardiomiopatia hipertrófica (CMH) ou morte súbita cardíaca
Diagnostic tests
1st tests to order
- eletrocardiograma (ECG)
- creatina quinase (CK)
- testes da função hepática
- testes de função renal
- Fragmento N-terminal do peptídeo natriurético tipo B (NT-proPNB)
- troponina
- urinálise
- radiografia torácica
- ecocardiografia transtorácica com Doppler
Tests to consider
- eletrocardiografia de esforço
- monitoramento com Holter
- teste ergométrico com cintilografia
- ressonância nuclear magnética cardíaca (RNMC)
- Tomografia computadorizada cardíaca (TC)
- arteriografia coronariana por tomografia computadorizada (TC)
- cateterismo cardíaco
- ecocardiografia sob estresse
- ecocardiografia por esforço
- ecocardiografia transesofágica
- biópsia endomiocárdica
- análise de mutações genéticas
Treatment algorithm
assintomático
sintomático: obstrução da via de saída do ventrículo esquerdo com função sistólica preservada (fração de ejeção ≥50%)
sintomático: não obstrutivo com função sistólica preservada (fração de ejeção ≥50%)
sintomático: com disfunção sistólica (fração de ejeção <50%)
Contributors
Authors
Theodore Abraham, MD
Professor of Medicine and Radiology
Meyer Friedman Distinguished Professor of Medicine
Co-director, UCSF HCM Center of Excellence
University of California
San Francisco
CA
Disclosures
TA serves as a steering committee member/local investigator and his institution has received research funding for hypertrophic cardiomyopathy-related clinical trials sponsored by Bristol Myers Squibb; Cytokinetics Inc.; Tenaya Pharmaceuticals; and Imbria Pharmaceuticals.
Acknowledgements
Dr Theodore Abraham would like to gratefully acknowledge Dr Monica Mukherjee, Dr Melanie D. Everitt, and Dr Anji T. Yetman, previous contributors to this topic.
Disclosures
MM, MDE, and ATY declare that they have no competing interests.
Peer reviewers
Radhika Kuna, MD
Fellow
Division of Cardiology
University of Maryland Medical Center
Baltimore
MD
Disclosures
RK declares that she has no competing interests.
Saidi Mohiddin, BSc, MBChB
Consultant Cardiologist/Head of Unit
Heart Muscle Disease Unit
Barts and The London NHS Trust
London
UK
Disclosures
SM declares that he has no competing interests.
Peer reviewer acknowledgements
BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.
Disclosures
Peer reviewer affiliations and disclosures pertain to the time of the review.
References
Key articles
Arbelo E, Protonotarios A, Gimeno JR, et al. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J. 2023 Oct 1;44(37):3503-626.Full text Abstract
Writing Committee Members, Ommen SR, Ho CY, et al. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association/American College of Cardiology Joint Committee on clinical practice guidelines. J Am Coll Cardiol. 2024 Jun 11;83(23):2324-405.Full text Abstract
Richard P, Charron P, Carrier L, et al. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation. 2003 May 6;107(17):2227-32. [Erratum in: Circulation. 2004 Jun 29;109(25):3258.]Full text Abstract
O'Mahony C, Jichi F, Pavlou M, et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J. 2014 Aug 7;35(30):2010-20.Full text Abstract
Pelliccia A, Sharma S, Gati S, et al. 2020 ESC guidelines on sports cardiology and exercise in patients with cardiovascular disease. Eur Heart J. 2021 Jan 1;42(1):17-96.Full text Abstract
Reference articles
A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.

Differentials
- Coração de atleta
- Estenose subaórtica distinta
- HVE causada por hipertensão
More DifferentialsGuidelines
- 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR guideline for the management of hypertrophic cardiomyopathy
- 2023 ESC Guidelines for the management of cardiomyopathies
More GuidelinesVideos
Galope de quarta bulha cardíaca
More videosLog in or subscribe to access all of BMJ Best Practice
Use of this content is subject to our disclaimer